Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02878928 · ClinicalTrials.gov registry record · NA

Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety

A NA study of Depression and Anxiety, sponsored by AltheaDx.

Completed
Registry status
NA
Development phase
579
Enrollment target
17
Study locations

NCT02878928 is a NA study of Depression and Anxiety that has completed, run by AltheaDx. The registered enrollment target is 579 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (26% lower). The trial reports 17 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02878928, a NA study of Depression and Anxiety, has completed, sponsored by AltheaDx.

COMPLETED
Registry status
NA
Development phase
579 participants
Enrollment target
17
Study locations

Study Summary

A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or anxiety disorders.

Conditions Studied

Interventions

  • GENETIC IDgenetix Neuropsychiatric Test Panel

Study Locations (17)

California

  • Adnab Research - Rolling Hills
  • Artemis Clinical Research - San Diego
  • Adnab Research - Torrance
  • Collaborative Neuroscience Network - Torrance

Florida

  • Innovative Clinical Research - Lauderhill
  • Innova Clinical Trials - Miami
  • APG Research - Orlando

Georgia

  • iResearch Atlanta - Decatur
  • Meridian Clinical Research - Savannah

New York

  • United Medical Associates - Binghamton
  • Richmond Behavioral Associates - Staten Island

Louisiana

  • Medpharmics - Metairie

Nebraska

  • Meridian Clinical Research - Norfolk

North Carolina

  • Carolina Partners in Mental HealthCare - Raleigh

Pennsylvania

  • Detweiler Family Medicine - Lansdale

Trial Details

FieldValue
Enrollment Target 579 participants
Start Date 2016-05
Est. Completion 2016-12
Phase NA

Sponsor

AltheaDx

4 total trials

What the Registry Record Tells You About NCT02878928

The ClinicalTrials.gov registry entry for NCT02878928 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 785-participant average among 679 other Depression trials with a reported enrollment target (26% lower). The listed sponsor is AltheaDx, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which IDgenetix Neuropsychiatric Test Panel is the first listed.

NCT02878928 reports 17 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02878928 about?

NCT02878928 is a clinical study titled "Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety". A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or anxiety disorders.

What is the current status of trial NCT02878928?

This trial is currently completed. It is a NA study. The enrollment target is 579 participants. The study started on 2016-05. Estimated completion is 2016-12.

What conditions does trial NCT02878928 study?

This clinical trial studies the following conditions: Depression, Anxiety.

What interventions are being tested in trial NCT02878928?

The interventions under investigation include: IDgenetix Neuropsychiatric Test Panel (GENETIC).

Who is sponsoring clinical trial NCT02878928?

This trial is sponsored by AltheaDx, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02878928 being conducted?

This trial has 17 study locations across California, Florida, Georgia, Louisiana, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.